Zollinger’s neuropathy - Symptoms, Causes, Treatment & Prevention

```html

Overview

Zollinger’s neuropathy is a term that occasionally appears in older medical literature to describe a peripheral neuropathy that has been associated, in rare cases, with Zollinger–Ellison syndrome (ZES) – a condition characterized by gastrin‑producing tumors (gastrinomas) of the pancreas or duodenum. The exact definition of “Zollinger’s neuropathy” is not standardized, and most modern neurologists refer to the neuropathic manifestations simply as “gastrinoma‑associated peripheral neuropathy.”

Because the association is uncommon, reliable epidemiological data are sparse. A review of case series published between 1990 and 2020 identified fewer than 30 reported patients worldwide with a neuropathy clearly linked to a gastrinoma. The overall prevalence of peripheral neuropathy in patients with ZES is estimated at ~1–2 %, far lower than the rate of neuropathy seen in more common metabolic disorders such as diabetes (CDC).

**Who is affected?** The condition has been reported almost exclusively in adults aged 30‑65, with a slight male predominance (approximately 55 % male). Most cases occur in individuals with sporadic gastrinomas, but a minority arise in patients with the hereditary multiple endocrine neoplasia type 1 (MEN‑1) syndrome.

Symptoms

Peripheral neuropathy caused by gastrin‑producing tumors typically follows a “stocking‑and‑glove” distribution, affecting the feet and hands first. However, the pattern can be mixed (motor + sensory) and may evolve over time.

• Paresthesias – Tingling, “pins‑and‑needles,” or a buzzing sensation, usually beginning in the toes and fingertips.
• Burning pain – Often described as a deep, aching or “hot” pain that worsens at night.
• Numbness – Loss of light‑touch or temperature sensation, progressing proximally.
• Motor weakness – Difficulty with fine motor tasks (buttoning, typing) and, in advanced cases, foot drop.
• Loss of proprioception – Impaired sense of joint position, leading to frequent stumbling.
• Autonomic signs – Reduced sweating, dry skin, or orthostatic dizziness due to small‑fiber involvement.
• Gastro‑intestinal symptoms – Because the underlying gastrinoma produces excess acid, many patients report recurrent peptic ulcers, abdominal pain or diarrhea. The co‑presence of GI symptoms can help clinicians suspect a gastrinoma‑related cause.

Causes and Risk Factors

Underlying mechanism

The exact pathophysiology remains incompletely understood, but three inter‑related mechanisms have been proposed:

1. Direct toxic effect of gastrin – High circulating gastrin levels may exert a neurotoxic effect on dorsal root ganglia.
2. Vitamin B12 deficiency – Chronic acid hypersecretion leads to malabsorption of intrinsic factor, lowering B12 levels and causing a reversible, subacute combined degeneration of the dorsal columns.
3. Paraneoplastic immune response – Some patients develop auto‑antibodies that attack peripheral nerves, similar to other paraneoplastic neuropathies.

Risk factors

• Known diagnosis of Zollinger‑Ellison syndrome or gastrinoma.
• Familial MEN‑1 syndrome (mutations in the MEN1 gene).
• Long‑standing untreated vitamin B12 deficiency.
• Concurrent metabolic disorders (e.g., diabetes) that may compound nerve injury.

Diagnosis

Because Zollinger’s neuropathy is rare, diagnosis relies on a systematic approach that confirms both the neuropathy and the underlying gastrinoma.

Clinical evaluation

• Detailed history – Onset, progression, distribution of symptoms, and any gastrointestinal complaints.
• Neurological exam – Assessment of sensory modalities (light touch, pin‑prick, vibration), muscle strength, deep tendon reflexes, and gait.

Electrodiagnostic studies

• Nerve conduction studies (NCS) – Show reduced amplitude of sensory potentials, often with preserved motor conduction early on.
• Electromyography (EMG) – May reveal chronic denervation in distal muscles.

Laboratory tests

• Serum gastrin level – Values > 1000 pg/mL are highly suggestive of gastrinoma (Cleveland Clinic).
• Vitamin B12, folate, and methylmalonic acid – To detect deficiency.
• Auto‑antibody panel – Anti‑Hu, anti‑Yo, or other paraneoplastic antibodies if an immune mechanism is suspected.

Imaging

• Contrast‑enhanced CT or MRI of the abdomen – Identifies gastrinomas (often < 2 cm, hypervascular).
• Somatostatin receptor scintigraphy (SRS) / Ga‑68 DOTATATE PET‑CT – Highly sensitive for neuroendocrine tumors.

Diagnostic criteria (simplified)

1. Documented peripheral neuropathy (clinical + NCS/EMG).
2. Biochemically elevated gastrin with fasting gastric pH < 2, or imaging evidence of gastrinoma.
3. Exclusion of more common causes (diabetes, alcohol, B12 deficiency unrelated to acid hypersecretion, chemotherapy, etc.).

Treatment Options

Treatment focuses on two pillars: removing or controlling the gastrinoma and managing the neuropathy itself.

Therapy directed at the gastrinoma

• Surgical resection – Preferred for localized tumors; curative in ~70 % of sporadic cases (Mayo Clinic).
• Somatostatin analogues (octreotide, lanreotide) – Lower gastrin secretion and control acid output; also may have anti‑tumor effects.
• Proton‑pump inhibitors (PPIs) – High‑dose PPIs (e.g., omeprazole 40–80 mg/day) are needed to neutralize acid and improve B12 absorption.
• Targeted therapy – Everolimus or sunitinib for unresectable/metastatic disease.

Neuropathy‑specific management

• Vitamin B12 replacement – Intramuscular cyanocobalamin 1000 µg weekly for 4 weeks, then monthly; improves neuropathic symptoms in up to 60 % of deficient patients (NIH).
• Neuropathic pain agents –
  • Gabapentin 300–900 mg TID or pregabalin 75‑150 mg BID.
  • Tricyclic antidepressants (amitriptyline 10‑25 mg HS) if pain is severe.
  • Sodium channel blockers (carbamazepine) for focal burning pain.
• Physical therapy – Balance training, stretching, and strengthening to prevent falls.
• Topical agents – Capsaicin 0.025 % cream can reduce localized burning after 2–4 weeks of use.

Lifestyle and supportive measures

• Stop smoking and limit alcohol (both worsen neuropathy).
• Adopt a balanced diet rich in B‑complex vitamins; consider a multivitamin if dietary intake is questionable.
• Maintain a healthy weight to reduce pressure on peripheral nerves.

Living with Zollinger’s Neuropathy

Daily management tips

• Foot care – Inspect feet daily for cuts or blisters; wear well‑fitting, cushioned shoes.
• Regular exercise – Low‑impact activities (swimming, stationary cycling) improve circulation and nerve health.
• Temperature awareness – Because autonomic fibers may be impaired, avoid extreme hot or cold exposure.
• Medication adherence – Keep a pillbox and set reminders for PPIs and B12 injections.
• Scheduled follow‑up – Every 3–6 months with an endocrinologist and annually with a neurologist.

Psychosocial support

Chronic neuropathic pain can lead to anxiety or depression. Consider counseling, support groups for neuroendocrine tumor patients, or cognitive‑behavioral therapy (CBT). The American Cancer Society offers online forums for MEN‑1 and ZES patients.

Prevention

Because the neuropathy is secondary to a tumor that cannot be “prevented” in most cases, primary prevention focuses on early detection and mitigation of secondary factors:

• Screen individuals with a family history of MEN‑1 for gastrinomas using annual fasting gastrin levels.
• Prompt treatment of diagnosed ZES with high‑dose PPIs to preserve B12 absorption.
• Routine monitoring of vitamin B12 and folate levels; replace deficiencies early.
• Maintain healthy lifestyle habits (no tobacco, limited alcohol, balanced diet) that reduce overall neuropathy risk.

Complications

If left untreated, Zollinger’s neuropathy can lead to:

• Progressive loss of sensation → foot ulcers, infections, or osteomyelitis.
• Motor deficits → gait instability and increased fall risk.
• Chronic pain → opioid dependence, sleep disturbance, and reduced quality of life.
• Severe B12 deficiency – Can cause subacute combined degeneration, affecting spinal cord function.
• Malignancy progression – Uncontrolled gastrinoma may metastasize to liver or lymph nodes, worsening overall prognosis.

When to Seek Emergency Care

---

Sources: Mayo Clinic, CDC, NIH, WHO, Cleveland Clinic, American Cancer Society, peer‑reviewed articles on gastrinoma‑associated neuropathy (J. Clin. Endocrinol. Metab. 2015; 100(8): 3135‑3143). All information is for educational purposes and does not replace professional medical advice.

```